Potent MEK1 and MEK2 inhibitor. Inhibits MEK activity in mouse colon 26 cells (IC50
= 0.33 nM). Inhibits the growth of melanoma cell lines in vitro
and in vivo
; induces G1
-phase cell cycle arrest and apoptosis in a mouse xenograft model. Also inhibits production of proangiogenic cytokines such as VEGF. Enhances generation of induced pluripotent stem cells (iPSCs). Orally active.
Soluble to 25 mM in DMSO
Store at -20°C
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold for research purposes under agreement from Pfizer Inc.
Growth-inhibitor and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations.
Ciuffreda et al.
A chemical platform for improved induction of human iPSCs.
Lin et al.
The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901.
Barrett et al.
The biological profile of PD 0325901: a second generation analog of CI-1040 with improved pharmaceutical potential.
Sebolt-Leopold et al.
Proc.Amer.Assoc.Cancer Res., 2004;45:925
The citations listed below are publications that use Tocris products. Selected citations for PD 0325901 include:
Showing Results 1 - 9 of 9